Evidence map›Paper›PMID 35228268›Full record

ArticleEuropean journal of hospital pharmacy : science and practice2023

Improvement in RAID questionnaire results in patients with rheumatoid arthritis treated with advanced therapies.

Andrea Rodríguez Esquíroz, Amaya Arrondo Velasco, Amaia Egüés Lugea, Maite Sarobe Carricas

Abstract read
In one paragraph

Article in European journal of hospital pharmacy : science and practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrea Rodríguez EsquírozPharmacy, University Hospital of Navarre, Pamplona, Navarra, Spain andrea.rodriguez.esquiroz@navarra.es.
Amaya Arrondo VelascoPharmacy, University Hospital of Navarre, Pamplona, Navarra, Spain.
Amaia Egüés LugeaPharmacy, University Hospital of Navarre, Pamplona, Navarra, Spain.
Maite Sarobe CarricasPharmacy, University Hospital of Navarre, Pamplona, Navarra, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo analyse the changes in patient-reported outcomes after starting advanced antirheumatic treatment.

methodsThe study included all patients who started self-administered biological or targeted synthetic treatments for rheumatoid arthritis between February and November 2020. The patients were given the RAID quality of life questionnaire to complete before starting the treatment and after 4 months. Univariate and multivariate analyses were performed to determine the association between patients' clinical and sociodemographic characteristics and quality of life improvement. The level of significance was set at 0.05.

resultsForty-six patients were included. Their ratings in the RAID questionnaire were improved after 4 months of treatment, both in the final overall total, which improved by 1.63±2.29 points, and in the different subtopics of the questionnaire (range 0-10). Pain was the domain that improved the most (2.33±2.82 points), followed by functional disability (2.15±2.51) and physical well-being (1.96±3.18). The improvement was statistically significant in all domains except the sleep score, which showed no statistically significant difference between the two time points analysed.

conclusionsAdvanced antirheumatic treatment improves the quality of life of patients after 4 months of treatment.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidHumansQuality of LifeSurveys and QuestionnairesAntirheumatic Agentsmental healthpain managementquality of health carerheumatologySafety

Identifiers

PMID35228268
PMCPMC10800251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.